Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business alliance4978ReproCELL Incorporated
Alliance partnerTokai National Higher Education and Research System (Center for Maternal and Perinatal Care, Nagoya University Hospital)
About the partner
Business DescriptionThe Center for Maternal and Perinatal Care at Nagoya University Hospital, which possesses relevant technologies and expertise
Impact on Business Performance
The impact of this matter on consolidated financial results for the current fiscal year is currently expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | Tokai National Higher Education and Research System (Center for Maternal and Perinatal Care, Nagoya University Hospital) |
| Alliance partner's business activities | The Center for Maternal and Perinatal Care at Nagoya University Hospital, which possesses relevant technologies and expertise |
| Type of alliance | Business alliance |
| Impact on Business Performance | The impact of this matter on consolidated financial results for the current fiscal year is currently expected to be immaterial. |
Items this document does not state (19)
Alliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop new treatments for neurological diseases using iPS cell technology by leveraging our technologies and expertise relating to iPS cells and those of the Center for Maternal and Perinatal Care at Nagoya University Hospital.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.